Inactivation of p21WAF1 sensitizes cells to apoptosis via an increase of both p14ARF and p53 levels and an alteration of the Bax/Bcl-2 ratio

被引:109
作者
Javelaud, D [1 ]
Besançon, F [1 ]
机构
[1] Inst Curie, INSERM, U365, F-75248 Paris 05, France
关键词
D O I
10.1074/jbc.M204497200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
p21(WAF1) appears to be a major determinant of the cell fate in response to anticancer therapy. It was shown previously that HCT116 human colon cancer cells growing in vitro enter a stable arrest upon DNA damage, whereas cells with a defective p21(WAF1) response undergo apoptosis. Here we report that the enhanced sensitivity of HCT116/p21(-/-) cells to chemotherapeutic drug-induced apoptosis correlates with an increased expression of p53 and a modification of their Bax/Bcl-2 ratio in favor of the pro-apoptotic protein Bax. Treatment of HCT116/p21(-/-) cells with daunomycin resulted in a reduction of the mitochondrial membrane potential and in activation of caspase-9, whereas no such changes were observed in HCT116/p21(+/+) cells, providing evidence that p21(WAF1) exerts an antagonistic effect on the mitochondrial pathway of apoptosis. Moreover, the role of p53 in activation of this pathway was demonstrated by the fact that inhibition of p53 activity by pifithrin-a reduced the sensitivity of HCT116/p21(-/-) cells to daunomycin-induced apoptosis and restored a Bax/Bcl-2 ratio similar to that observed in HCT116p21(-/-) cells. Enhancement of p53 expression after disruption of p21(WAF1) resulted from a stabilization of p53, which correlated with an increased expression of the tumor suppressor p14(ARF), an inhibitor of the ubiquitin ligase activity of Mdm2. In accordance with the role of p14ARF in p53 stabilization, overexpression of p14(ARF) in HCT116/p21(+/+) cells resulted in a strong increase in p53 activity. Our results identify a novel mechanism for the antiapoptotic effect of p21(WAF1) consisting in maintenance of mitochondrial homeostasis that occurs in consequence of a negative control of p14(ARF) expression.
引用
收藏
页码:37949 / 37954
页数:6
相关论文
共 48 条
  • [1] Life-or-death decisions by the Bcl-2 protein family
    Adams, JM
    Cory, S
    [J]. TRENDS IN BIOCHEMICAL SCIENCES, 2001, 26 (01) : 61 - 66
  • [2] Apoptosis inhibitory activity of cytoplasmic p21Cip1/WAF1 in monocytic differentiation
    Asada, M
    Yamada, T
    Ichijo, H
    Delia, D
    Miyazono, K
    Fukumuro, K
    Mizutani, S
    [J]. EMBO JOURNAL, 1999, 18 (05) : 1223 - 1234
  • [3] p14ARF links the tumour suppressors RB and p53
    Bates, S
    Phillips, AC
    Clark, PA
    Stott, F
    Peters, G
    Ludwig, RL
    Vousden, KH
    [J]. NATURE, 1998, 395 (6698) : 124 - 125
  • [4] Evidence for a role of NF-κB in the survival of hematopoietic cells mediated by interleukin 3 and the oncogenic TEL/platelet-derived growth factor receptor β fusion protein
    Besançon, F
    Atfi, A
    Gespach, C
    Cayre, YE
    Bourgeade, MF
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (14) : 8081 - 8086
  • [5] Rescuing the function of mutant p53
    Bullock, AN
    Fersht, A
    [J]. NATURE REVIEWS CANCER, 2001, 1 (01) : 68 - 76
  • [6] Disruption of p53 in human cancer cells alters the responses to therapeutic agents
    Bunz, F
    Hwang, PM
    Torrance, C
    Waldman, T
    Zhang, YG
    Dillehay, L
    Williams, J
    Lengauer, C
    Kinzler, KW
    Vogelstein, B
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1999, 104 (03) : 263 - 269
  • [7] Deregulated β-catenin induces a p53-and ARF-dependent growth arrest and cooperates with Ras in transformation
    Damalas, A
    Kahan, S
    Shtutman, M
    Ben-Ze'ev, A
    Oren, M
    [J]. EMBO JOURNAL, 2001, 20 (17) : 4912 - 4922
  • [8] p21WAF1/Cip1:: more than a break to the cell cycle?
    Dotto, GP
    [J]. BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2000, 1471 (01): : M43 - M56
  • [9] Esteller M, 2000, CANCER RES, V60, P129
  • [10] Human ARF binds E2F1 and inhibits its transcriptional activity
    Eymin, B
    Karayan, L
    Séité, P
    Brambilla, C
    Brambilla, E
    Larsen, CJ
    Gazzéri, S
    [J]. ONCOGENE, 2001, 20 (09) : 1033 - 1041